Kevin Kalinsky, MD, MS, on the Aim of the Phase 3 RxPONDER Trial in Breast Cancer Subtype

Video

A recent study sought to evaluate the 21-gene Oncotype Dx Recurrence Score in nonmetastatic HR-positive, HER2-negative breast cancer.

In a recent study, investigators aimed to evaluate the 21-gene Oncotype Dx Recurrence Score in nonmetastatic HR-positive, HER2-negative breast cancer to determine if women may be overtreated or undertreated.

They found that postmenopausal women with 1 to 3 positive nodes and recurrence score between 0 and 25 can likely forego adjuvant chemotherapy without compromising invasive disease-free survival, according to Kevin Kalinsky, MD, MS.

“[Our results have] huge implications for when we sit down with our patients, and we explain to them, ‘Well, listen, these are the benefits and these are the risks,’” he explained. “This study helps inform those discussions.”

Kalinsky, acting associate professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine, director of the Glenn Family Breast Center, and director of breast medical oncology at Winship Cancer Institute of Emory University, spoke with CancerNetwork® about the aim of the phase 3 RxPONDER trial (NCT01272037).

Transcription:

This study was looking to answer the question of patients who had a recurrence for the Oncotype Dx 21-gene Recurrence Score and if that was 25 or less. We randomized patients to chemotherapy followed by undergoing therapy versus therapy alone…the primary aim was to see [if] those patients [had] a lower recurrence [risk] or if there was benefit from chemotherapy–a little bit different than those patients who are at the higher end of that recurrence score. While we didn’t see that, the reason we’re recording these data now is that we’re seeing a very different sort of benefit in patients who are premenopausal compared with post[menopausal].

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
Related Content